Jasper Therapeutics, Inc. (JSPR) stock
JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$13.37−1.39 (-9.42%)
Close on Nov 12, 2026Market cap $444.88MP/E –Yield –
Jasper Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Jasper Therapeutics's total assets was $11.80M at Jun 30, 2026. For fiscal 2025 it was $35.78M, down 55.2% from the year before. The highest annual figure on record is $101.69M in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.78M | -55.2% |
| FY2024 | Dec 31, 2024 | $79.90M | -15.8% |
| FY2023 | Dec 31, 2023 | $94.89M | +96.2% |
| FY2022 | Dec 31, 2022 | $48.36M | -48.4% |
| FY2021 | Dec 31, 2021 | $93.65M | +301.0% |
| FY2020 | Dec 31, 2020 | $23.36M | -77.0% |
| FY2019 | Dec 31, 2019 | $101.69M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $11.80M | -74.6% |
| Q1 FY2026 | Mar 31, 2026 | $21.18M | -63.2% |
| Q4 FY2025 | Dec 31, 2025 | $35.78M | -55.2% |
| Q3 FY2025 | Sep 30, 2025 | $57.47M | -42.2% |
| Q2 FY2025 | Jun 30, 2025 | $46.47M | -59.2% |
| Q1 FY2025 | Mar 31, 2025 | $57.60M | -54.3% |
| Q4 FY2024 | Dec 31, 2024 | $79.90M | -15.8% |
| Q3 FY2024 | Sep 30, 2024 | $99.41M | -19.9% |
| Q2 FY2024 | Jun 30, 2024 | $113.93M | -17.9% |
| Q1 FY2024 | Mar 31, 2024 | $125.96M | +160.5% |
| Q4 FY2023 | Dec 31, 2023 | $94.89M | +60.5% |
| Q2 FY2023 | Jun 30, 2023 | $124.17M | +76.5% |
| Q1 FY2023 | Mar 31, 2023 | $138.76M | +72.3% |
| Q4 FY2022 | Dec 31, 2022 | $48.36M | -48.4% |
| Q3 FY2022 | Sep 30, 2022 | $59.11M | -44.9% |
| Q2 FY2022 | Jun 30, 2022 | $70.37M | -30.0% |
| Q1 FY2022 | Mar 31, 2022 | $80.55M | -20.2% |
| Q4 FY2021 | Dec 31, 2021 | $93.65M | +301.0% |
| Q3 FY2021 | Sep 30, 2021 | $107.21M | +5.8% |
| Q2 FY2021 | Jun 30, 2021 | $100.55M | -1.0% |
| Q1 FY2021 | Mar 31, 2021 | $100.96M | -0.8% |
| Q4 FY2020 | Dec 31, 2020 | $23.36M | -77.0% |
| Q3 FY2020 | Sep 30, 2020 | $101.32M | – |
| Q2 FY2020 | Jun 30, 2020 | $101.60M | – |
| Q1 FY2020 | Mar 31, 2020 | $101.79M | – |
| Q4 FY2019 | Dec 31, 2019 | $101.69M | – |
See a number that looks wrong?